Drug Search Results
More Filters [+]

Tecadenoson

Alternative Names: tecadenoson
Latest Update: 2023-06-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: ADORA1 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tecadenoson

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Atrial Fibrillation

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CVT 4129

P2

Completed

Atrial Fibrillation

2008-04-01

Recent News Events